Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
HOME > COMMENTARY
COMMENTARY
-
Epigenetic Drug Discovery Efforts Expanding, with Solid Cancers Now Being Targeted
September 1, 2017
-
MHLW Panel Elaborating Rules for Clinical Research Law, “Scholarship Donations” to Be a Major Focus
August 21, 2017
-
Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics
July 26, 2017
-
Did Voice of the Industry Reach Honebuto Policymakers?
June 21, 2017
-
As AG Momentum Continues, Mucosta AG to Hit Shelves 8 Years after Gx Entry
June 14, 2017
-
MHLW, MOF Agreed on CEFP Working Group Report, Continuation of Premium As-Is Seems Difficult
May 11, 2017
-
Will Government Take the Lead in Pricing Debate towards 2017 Fiscal Blueprint?
April 19, 2017
-
“Cash-and-Carry Dealers” and Their Peculiar Business Practices in the Spotlight in Wake of Counterfeit Harvoni Scandal
April 12, 2017
-
Is the Government’s 70% Interim Generic Share Target Achievable?
March 13, 2017
-
Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
March 7, 2017
-
Will NHI Pricing Reform in Sluggish Domestic Market Trigger Industry Reorganization?
February 6, 2017
-
Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
January 30, 2017
-
Hepatology Society Revises Hep C Treatment Guidelines; Looking to Future Research for Non-Responders to IFN-Free Treatment
December 14, 2016
-
Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
November 15, 2016
-
Are Biosimilars on Verge of Breakthrough in Japan? Initiatives Underway to Prepare for Full-Scale Entry of Major Biosimilars
October 25, 2016
-
Policymakers Face Balancing Act over Opdivo Re-Pricing
October 17, 2016
-
Can Wholesalers Bear Distribution Costs amid 90% Discount on Generics?
October 11, 2016
-
Can Mid-sized Makers Break Away from Long-Listed Product Model?
August 19, 2016
-
MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
June 28, 2016
-
7 Drugs Picked for Cost-Effective Assessments, but Now How Will They Be Re-Priced Exactly?
May 27, 2016
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…